Another observational study has questioned whether Impella ventricular assist pumps (Abiomed) should be used in patients with acute myocardial infarction (MI) complicated by cardiogenic shock (CS), at ...

The goal of the trial was to evaluate treatment with an Impella percutaneous left ventricular assist device (LVAD) compared with an intra-aortic balloon pump (IABP) in patients with cardiogenic shock ...

NEW ORLEANS – The Impella 5.0 and 5.5 left ventricular assist device failed to measure up on outcomes when used for high-risk patients undergoing ventricular tachycardia (VT) ablation therapies, ...

Patients undergoing PCI for acute MI complicated by cardiogenic shock (AMICS) had worse outcomes—including more mortality and bleeding—when their hemodynamic support during that hospitalization was ...

DANVERS, Mass.--(BUSINESS WIRE)--The United States Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for Impella RP to include patients suffering from COVID-19 related ...

Abiomed Inc., has worked the ventricular assist device (VAD) space for a number of years with its Impella series of VADs, and a study coming out of Japan seems to affirm investors’ confidence in these ...

For patients who have acute MI with cardiogenic shock (AMICS), Medicare claims data aren’t detailed enough to show whether use of the Impella percutaneous microaxial left ventricular assist device ...

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed’s (NASDAQ: ABMD) newest heart pump, the Impella 5.5 with SmartAssist, has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for safety ...

Scientists have succeeded in minimally invasive treatment of a patient with acute heart failure due to medical treatment-resistant cardiogenic shock by making use of Impella, a percutaneous auxiliary ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Abiomed announced a recall of its LVAD due to ...

DANVERS, Mass.--(BUSINESS WIRE)-- The United States Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for Impella RP to include patients suffering from COVID-19 ...